Thrombectomy Aids in Medium-Vessel Occlusion Stroke Recovery

A new randomized controlled trial in China demonstrates that endovascular thrombectomy, when combined with medical management, improves recovery outcomes for patients with acute ischemic stroke caused by medium-vessel occlusion. Conducted from 2023 to 2025, the study involved 564 adults (median age 71, 43% female) presenting within 24 hours of symptom onset with moderate-to-severe deficits. Patients were randomly assigned to receive either thrombectomy plus medical management (281 participants) or medical management alone (283 participants). The primary outcome measured functional disability at 90 days using modified Rankin Scale (mRS) scores. Results showed that 59% of the thrombectomy group achieved functional independence (mRS 0-2) compared to 47% in the control group, with an adjusted rate ratio of 1.24. Excellent outcomes (mRS 0-1) were also more common in the thrombectomy group (49% vs. 33%, aRR 1.47). However, symptomatic intracranial hemorrhages occurred in 5% of the thrombectomy group versus 2% in the control group. Secondary analyses revealed no significant difference in 90-day mortality between the two groups (11% vs. 10%). Researchers noted that patients with younger age, higher stroke severity, and early presentation without prior thrombolysis may benefit most from the procedure. The study was co-led by Wei Hu, MD, and Xiaozhong Jing, MD, of the University of Science and Technology of China, along with collaborators from institutions in Dalian, Shanghai, Fuzhou, and Pittsburgh. Limitations included a small proportion of patients receiving intravenous thrombolysis, exclusion of those with mild deficits, and potential bias from telephone-based functional assessments. The study was funded by the National Natural Science Foundation of China and the Noncommunicable Chronic Diseases National Science and Technology Major Project. Findings were published in *The New England Journal of Medicine* on May 13, 2026.